Heterogeneity of weight gain after initiation of Elexacaftor/Tezacaftor/Ivacaftor in people with cystic fibrosis
Abstract Background The introduction of the novel therapy, Elexacaftor/Tezacaftor/Ivacaftor (ETI) has been effective in improving weight gain in both clinical trials and real-world studies. However, the magnitude of this effect appears to be heterogeneous across patient subgroups. This study aims to...
| Main Authors: | , , , , , , , , , |
|---|---|
| 格式: | Article |
| 語言: | English |
| 出版: |
BMC
2023-06-01
|
| 叢編: | Respiratory Research |
| 主題: | |
| 在線閱讀: | https://doi.org/10.1186/s12931-023-02451-0 |